Document:

<PAGE>

        CONFIDENTIAL TREATMENT                          EXHIBIT 10.21

                WEB SOFTWARE LICENSING AND DEVELOPMENT AGREEMENT

     This Web Software Licensing and Development Agreement is entered into as of
September 10, 1999 (the "Effective Date") between AWARE, Inc. ("AWARE") and eMed
Technologies Corporation ("EMED"), formerly known as ACCESS Radiology
Corporation.

                                   Background
                                   ----------

  1. EMED is in the business of providing integrated hardware and software
systems and services with respect to the transmission and interpretation of
medical images.
AWARE develops and licenses proprietary computer software that is useful for
compression and web-based viewing of digital images.

  2. AWARE and EMED are parties to a Software Licensing and Development
Agreement dated May 30, 1997 (the "1997 Agreement"). The 1997 Agreement provides
for the licensing of various software by AWARE to EMED on the terms set forth
therein. Among other things, the 1997 Agreement contemplated the development,
licensing and marketing of certain new software, referred to in the 1997
Agreement as the "Joint Product". The 1997 Agreement sets forth procedures under
which the Joint Product would be developed and licensed, royalties would be
negotiated, and ownership of intellectual property would be determined.

  3. The development efforts contemplated with respect to the Joint Product by
the 1997 Agreement have now resulted in the initial commercial release of a
software application for the web-based viewing and distribution of medical
images and related information. This release having occurred, AWARE and EMED now
wish to provide for definitive terms upon which this new software will be
licensed and marketed, and upon which further development work relating to the
new software will proceed.

  NOW, THEREFORE, the parties agrees as follows:

                            CONFIDENTIAL TREATMENT

                                       1
<PAGE>

                     I. MODIFICATION OF THE 1997 AGREEMENT.

  1.01. Termination of Joint Product Provisions. Article III of the 1997
        ---------------------------------------
Agreement, which provides for various matters relating to the "Joint Product" as
defined therein, shall terminate upon the execution of this Agreement. In
addition, references to the Joint Product in Articles IV, V and VI of the 1997
Agreement shall have no further force or effect upon the execution of this
Agreement. The rights and obligations of AWARE and EMED with respect to the Web
Product and the related Licensed Software (as defined in Section 2.01 of this
Agreement), and with respect to the Joint Product (as defined Article III of
this Agreement)shall be governed exclusively by this Agreement, and not by the
1997 Agreement. The rights and obligations of AWARE and EMED with respect to the
"Compression Software" (as defined in the 1997 Agreement) shall be governed
exclusively by the 1997 Agreement, and not by this Agreement.

  1.02 Survival of the 1997 Agreement. The 1997 Agreement shall survive the
       -------------------------------
execution of this Agreement and shall continue to govern the rights and
obligations of the parties with respect to the "Compression Software" (as
defined in the 1997 Agreement), except to the extent expressly modified by this
Agreement.  The references to "Schedule I" in Sections 1.01, 1.03(b), 1.04(a),
and 2.02(b) of the 1997 Agreement are amended to refer to "the documentation
separately supplied by AWARE".

                      II. LICENSING OF SOFTWARE; PAYMENTS.

  2.01 Grant of License. Subject to the terms of this Agreement, AWARE grants to
       -----------------
EMED the following rights, under any patent, copyright, trade secret or other
proprietary right (other than any trademark) of AWARE, whether presently held or
hereafter acquired, with respect to (i) the proprietary web-based image viewing
and distribution software identified on Schedule I and any upgrades or
modifications thereof (the "Web Product") and (ii) any other web-based image
viewing or distribution software developed by AWARE pursuant to this Agreement
(such software and the Web Product being referred to collectively as the
"Licensed Software"):

                            CONFIDENTIAL TREATMENT

                                       2
<PAGE>

           (a) The right to use the Licensed Software for internal purposes and
     in support of users of EMED products for Medical Use, and to use and make
     available the Licensed Software as part of EMED's product line and for
     integration with other components of EMED products.

           (b) The right to grant sublicenses of the Licensed Software for
     Medical Use to users of EMED products and to original equipment
     manufacturers or other parties which utilize toolkits to create derivative
     products for Medical Use which are in turn licensed to end users.
     Sublicenses of software will be granted in compliance with the procedures
     set forth in Section 6.01.

           (c) The right to modify the Licensed Software to create new releases
     and new products for Medical Use, and to grant sublicenses of software as
     modified for Medical Use to users and to original equipment manufacturers
     or other parties which utilize toolkits to create derivative products for
     Medical Use which will in turn be licensed to end users. Sublicenses of
     software will be granted in compliance with the procedures set forth in
     Section 6.01.

For purposes of the Agreement, "Medical Use" means the compression,
transmission, viewing or other processing of medical images. The rights granted
to EMED shall be exclusive to the extent set forth in Article III.

  2.02. License Fees. (a) License fees payable to AWARE with respect to the Web
        ------------
Product will be determined based upon the terms on which the Web Product is made
available to customers. EMED expects to offer the Web Product to customers under
a plan in which the customer's initial payment upon installation of the Web
Product would be [*THE CONFIDENTIAL PORTION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] Licenses granted under
such a plan are referred to as "Subscription Sales". Customers are also expected
to be offered the [*THE CONFIDENTIAL PORTION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] License fees payable
with respect to Subscription Sales will be calculated as provided in subsection
(b) below, and license fees payable with respect to all other sales of licenses
of

                            CONFIDENTIAL TREATMENT

                                       3
<PAGE>

the Web Product will be calculated as provided in subsection (c) below.

  (b) With respect to each Subscription Sale of the Web Product, EMED will pay
to AWARE [*THE CONFIDENTIAL PORTION HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION.] of Net Client License Revenue (as
defined in subsection (d) below) attributable to licenses of the client portion
of the Web Product. These fees are in addition to, and not in lieu of, the
license fees payable for compression software under the 1997 Agreement.

  (c) With respect to sales of the Web Product other than Subscription Sales,
EMED will pay to AWARE [*THE CONFIDENTIAL PORTION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] of Net Software License
Revenue.

  (d) Net Client License Revenue means amounts paid to EMED in Subscription
Sales for [*THE CONFIDENTIAL PORTION HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION] (excluding taxes, shipping, insurance,
the interest portion of payments under rental or leasing arrangements, actual
customer returns, customs duties, and any charges for services).

  (e) Net Software License Revenue means amounts paid to EMED by customers for
[*THE CONFIDENTIAL PORTION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION] (excluding taxes, shipping, insurance, the
interest portion of payments under rental or leasing arrangements, actual
customer returns, customs duties, and any charges for services), [*THE
CONFIDENTIAL PORTION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION.

                      ] "High End Storage and Network Hardware" is defined in
Schedule II.

                            CONFIDENTIAL TREATMENT

                                       4
<PAGE>

  (f) No royalties shall be payable under this Section 2.02 for beta testing
installations, or demonstration or loaner units. The duration of beta testing
will be limited to a period of time no longer than that which is determined by
EMED to be reasonably necessary for satisfaction of the requirements for
commercial marketing of the product or release being tested. Loaner units will
be provided for a period of time no longer than that which is reasonably
necessary for the customer to assess the functionality and desirability of the
product or release being loaned. EMED will not make the Web Product available
without charge except for (i) beta testing installations, demonstration or
loaner units and (ii) copies of client software provided to radiologists in
connection with Subscription Sales, and EMED will not make the Web Product
available without charge to assist in selling other products or in generating
revenues from other sources.

  2.03. Payments. (a) Promptly after the end of each calendar quarter, EMED will
        --------
deliver to AWARE a statement setting forth, for such quarter, the number of
copies of server software included in Subscription Sales, Net Client License
Revenue, and Net Software License Revenue. Each quarterly statement shall be
accompanied by payment of license fees due. EMED will use its best efforts to
provide such statement and pay license fees due within 30 days of the end of
each calendar quarter. Each quarterly statement and payment of license fees
shall be provided no later than 60 days after the end of the relevant calendar
quarter.

  (b) EMED will keep complete books of account containing all particulars that
may be necessary to determine the amounts payable to AWARE hereunder. Such books
and supporting data shall be open for inspection for one year following the
calendar year to which they pertain, at reasonable times and upon reasonable
notice, by an independent auditor for purposes of verifying the statements
delivered pursuant to subsection (a) above. AWARE will not conduct more than one
such inspection for books and supporting data relating to any single calendar
year. The results of any inspection shall be made available to EMED. If the
agreed results of an inspection show an underpayment or overpayment, then EMED
shall pay to AWARE the amount of any underpayment and AWARE shall pay to EMED
the amount of any overpayment. If the agreed results of such inspection show
that EMED has underpaid AWARE by [*THE CONFIDENTIAL PORTION HAS BEEN OMITTED AND
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] then EMED shall
pay to AWARE the reasonable and

                            CONFIDENTIAL TREATMENT

                                       5
<PAGE>

documented out of pocket costs of conducting such inspection, and allow
inspection of the books and supporting data for the prior two years. AWARE shall
otherwise bear the costs it incurs in performing any inspection.

  2.04. Other Products. With respect to Licensed Software that may be developed
        --------------
in the future, the parties will negotiate in good faith to determine definitive
terms. It is the intention of the parties that license fees shall be consistent
with the rate of [*THE CONFIDENTIAL PORTION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION] of Net Software License
Revenue as described in this Agreement.

                      III. MARKETING FOR NON-MEDICAL USE.

     3.01 AWARE shall have the exclusive right to market software and other
components included in the Web Product and any other software developed pursuant
to this Agreement (the "Joint Product"), under any patent, copyright, trade
secret or other proprietary right of EMED (other than any trademark), whether
presently held or hereafter acquired, for all uses other than Medical Use. AWARE
shall have the following rights with respect to the Joint Product, which EMED
hereby grants to AWARE.

           (a) The right to use the Joint Product for internal purposes and in
     support of users of AWARE products, and to use and make available the Joint
     Product as part of AWARE's product line and for integration with other
     components of AWARE products, in all cases for uses other than Medical Use.
     Medical Use includes grants of licenses to indemnity insurance companies,
     and AWARE will not grant any such licenses.

           (b) The right to make and have made, use and have used, and sell,
     lease or otherwise transfer the Joint Product, and to grant sublicenses of
     the software and other intellectual property included in the Joint Product
     to users of AWARE products in which such software is included, in all cases
     for uses other than Medical Use. Users to whom sublicenses are granted may
     include original equipment manufacturers

                            CONFIDENTIAL TREATMENT

                                       6
<PAGE>

     or other parties which utilize toolkits to create derivative products for
     any use other than for Medical Use, which will in turn be licensed to end
     users. Sublicenses of software will be granted in compliance with the
     procedures set forth in Section 7.01.

           (c) The right to modify the Joint Product and the software included
     in it to create new releases and new products, to make and have made, use
     and have used, and sell, lease or otherwise transfer products including
     modifications, and to grant sublicenses of software as modified to users of
     AWARE products in which such software is included, in all cases for uses
     other than Medical Use. Users to whom sublicenses are granted may include
     original equipment manufacturers or other parties which utilize toolkits to
     create derivative products for any use other than for Medical Use, which
     will in turn be licensed to end users. Sublicenses of software will be
     granted in compliance with the procedures set forth in Section 7.01.

     3.02. AWARE shall pay royalties to EMED for licenses granted under this
Article III in amounts to be agreed between EMED and AWARE, and at intervals and
under procedures substantially the same as those set forth for payments by EMED
in Section 2.03. The royalties payable to EMED shall be a percentage (the
"Royalty Percentage") of amounts paid to AWARE for license of the Joint Product.
The Royalty Percentage shall be a percentage of not less than [*The confidential
portion has been omitted and filed separately with the Securities and Exchange
Commission.] which shall reflect the contribution of EMED during the term of
this Agreement to aspects of the Joint Product developed for uses other than
Medical Use.  The Royalty Percentage will be determined based upon the principle
that the Royalty Percentage will be fixed at [*The confidential portion has been
omitted and filed separately with the Securities and Exchange Commission.] if
EMED contributes little or nothing to during the term of this Agreement to
aspects of the Joint Product developed for uses other than Medical Use, and will
approach [*The confidential portion has been omitted and filed separately with
the Securities and Exchange Commission.] if EMED contributes significantly to
such aspects.  The exact percentage will depend on the mutual agreement of the
parties as to the significance of EMED's contribution.  Promptly upon completion
of the functional product descriptions and design specifications

                            CONFIDENTIAL TREATMENT

                                       7
<PAGE>

for the Joint Product, AWARE and EMED will negotiate in good faith to reach
agreement on the Royalty Percentage. As it is not contemplated that EMED will
contribute development efforts to aspects of the Joint Product other than
Medical Use, if no agreement is reached within [*The confidential portion has
been omitted and filed separately with the Securities and Exchange Commission.]
days, the Royalty Percentage shall be fixed at [*The confidential portion has
been omitted and filed separately with the Securities and Exchange Commission.]
Except as agreed in writing with EMED, AWARE will not make the Joint Product
available without charge.

                                IV. EXCLUSIVITY

  4.01 Exclusivity Commitments. (a) EMED shall have the exclusive right to use
       -----------------------
and sublicense software developed or owned by AWARE for Medical Use to the
extent set forth herein. From the date of this Agreement until the termination
of exclusivity as provided in Section 6.01, AWARE will not (except as expressly
permitted by this Agreement) supply for Medical Use or permit any person to use
for Medical Use (i) the Web Software or any modification or improvement of the
Web Software or (ii) any other dynamic HTML or plug-in product that is
developed, owned or licensed by AWARE. AWARE will take reasonable steps to
assure compliance with this exclusivity commitment by  third parties to whom
AWARE provides software. Notwithstanding anything contained in this Agreement,
AWARE may provide its ADSL, SDSL, HFC and any other general data communication
product to third parties for Medical Use or any other purpose.

  (b) From the date of this Agreement until the termination of exclusivity as
provided in Section 6.01, AWARE will be the exclusive supplier to EMED of web-
based image viewing and distribution software for use in EMED products. EMED
will not independently develop any such software and will not include any such
software (other than that developed by or in cooperation with AWARE under this
Agreement) in the Web Product or any product that is competitive with the Web
Product. The parties understand and agree that home, diagnostic and intensive
care unit viewers are complementary to the Web Product and are therefore not
within the scope of the foregoing restrictions.

                            CONFIDENTIAL TREATMENT

                                       8
<PAGE>

  4.02. Exceptions. (a) Licenses of software for Medical Use which have been
        ----------
previously granted and for which all license fees have been invoiced as of the
date of this Agreement shall continue in effect notwithstanding Section 4.01.
However, AWARE will not provide upgrades or new releases for any software
subject to such licenses except as expressly permitted in this Section 4.02.

  (b) Notwithstanding Section 2.01, AWARE may continue to perform its
contractual obligations to a party previously identified to EMED by AWARE
through July 30, 2000.

  (c) Notwithstanding section 2.01, AWARE may until December 30, 1999 grant to a
second party previously identified to EMED by AWARE, licenses for Medical Use of
compression libraries and plugins, and may permit such party to include copies
of such software in equipment made available to end users. During the period
from the effectiveness of this agreement until December 30, 1999 AWARE shall
not improve in any material way the functionality of the software licensed to
this party.

  4.03. Transition. Promptly after the date of this Agreement, AWARE will
        ----------
publicly announce that it has enlarged its exclusive relationship with EMED and
that EMED and AWARE are making a commitment to the Web Product. This
announcement will be subject to review by EMED before its release. EMED may
disclose the relationship between AWARE and EMED contemplated by this Agreement
in technical and product oriented marketing materials without review by AWARE.
EMED may disclose this Agreement and the relationship contemplated hereby in
filings with securities regulators to the extent set forth in Section 7.06. All
other public announcements by EMED that refer to AWARE will be subject to review
by AWARE prior to their release.

                          V. DUTIES OF EMED AND AWARE

  5.01. Duties of EMED. EMED will use its best efforts to maximize the market
        --------------
and sales volume for the Web Product. EMED will dedicate full-time engineering
management, and make substantial and continued resources available for sales,
marketing, support, installation and training for the Web Product. EMED will
continue to make modifications to its core image server (Compression Server)
products to accommodate greater functionality, performance,

                            CONFIDENTIAL TREATMENT

                                       9
<PAGE>

and reliability of the complete product offering. EMED will also either develop
or source other products that improve the functionality and marketability of
EMED's web and client/server products as appropriate in the judgment of EMED.

  5.02. Duties of AWARE. AWARE will continue to provide primary engineering
        ---------------
application development for EMED's web-based image viewing and distribution
software for use in EMED products including the client software and dynamic HTML
generation applications included in the Web Product. AWARE's responsibilities
will specifically include bug fixes, work-arounds and other software support as
needed to cause the Licensed Software to perform in accordance with its
specifications. AWARE will also make available, upon request by EMED, additional
applications, additional features on existing applications, and changes to core
technology as specified by EMED. AWARE will dedicate to these activities a
minimum of [*THE CONFIDENTIAL PORTION HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION.] qualified full-time software engineers
who are knowledgeable in compression and web technology, a part time test
engineer, and additional engineering management resources as required.

  5.03. Meetings. Management of AWARE and EMED will meet on a monthly basis to
        ---------
review technical and market progress towards meeting goals and objectives.

                                    VI. TERM

  6.01. Term; Effect of Expiration. (a) The initial term of this Agreement shall
        --------------------------
extend until December 31, 2005. The term of this Agreement may be renewed by
mutual agreement of the parties.

  (b) If the term of this Agreement shall expire (and this Agreement shall not
have been terminated for breach pursuant to Section 6.02), the licenses granted
in Section 2.01 and Section 3.01 shall remain in effect for five years from the
date of expiration; provided that such licenses shall be modified so that they
are no longer exclusive.

  (c) AWARE and EMED agree that the royalties and license fees payable under
this Agreement shall be modified effective upon modification of the licenses
granted

                            CONFIDENTIAL TREATMENT

                                       10
<PAGE>

hereunder pursuant to subsection (b) above. AWARE and EMED further agree
that the appropriate amount of such modified royalties and license fees cannot
be determined as of the date of this Agreement. AWARE and EMED shall negotiate
in good faith for at least three months after effectiveness of license
modification pursuant to subsection (b) to reach agreement on modified license
fees and royalties. If, at any time after the end of such three month period,
either party shall determine in its judgment that negotiations are unlikely to
result in an acceptable outcome, such party may initiate arbitration to
determine modified fees and royalties pursuant to the procedures specified in
Section 8.01.

  6.02. Termination for Breach. (a) If EMED shall materially breach its
        -----------------------
obligations under this Agreement, and such material breach shall be continuing
for at least 60 days after delivery of a notice by AWARE describing such breach,
then AWARE may by a separate notice terminate this Agreement for breach under
this Section 6.02(a).

  (b) If AWARE shall materially breach its obligations under this Agreement, and
such material breach shall be continuing for at least 60 days after delivery of
a notice by EMED describing such breach, then EMED may by a separate notice
terminate this Agreement for breach under this Section 6.02(b).

  (c) With respect to the obligations of AWARE and EMED under Sections 5.01 and
5.02, "material breach" means willful failure of a party to allocate the
resources required by the Section 5.01 or 5.02 (as the case may be) to the
performance of such party's responsibilities.

  (d) Termination for breach under this Section 6.02 shall not be an exclusive
remedy, but shall be in addition to any other remedies that either party may
have.

     6.03. Effect of Termination for Breach. (a) If AWARE shall terminate this
           ---------------------------------
Agreement for breach pursuant to Section 6.02, then the license granted to EMED
pursuant to Section 2.01 shall immediately terminate and EMED shall cease using
or marketing the Licensed Software and the Web Product; provided that EMED shall
fulfill any maintenance obligations existing as of the effective date of such
termination. Upon the effectiveness of such a termination,

                            CONFIDENTIAL TREATMENT

                                       11
<PAGE>

the exclusivity obligations of AWARE pursuant to Article III shall terminate.

     (b) If EMED shall terminate this Agreement for breach pursuant to Section
6.02, then the license granted to EMED pursuant to Section 2.01 and the
exclusivity provisions binding upon AWARE pursuant to Article IV shall remain in
effect, and the exclusivity obligations of EMED pursuant to Article IV shall
terminate. In such event, AWARE shall continue to provide bug fixes, work-
arounds and other software support as needed to cause the Licensed Software to
perform in accordance with its specifications. Also in such event, EMED shall
retain source code delivered under Section 7.03, AWARE shall deliver to EMED any
additional source code of the Licensed Software not previously delivered under
Section 7.03, and EMED shall continue to have the right to modify the Licensed
Software. For so long as the license granted under Section 2.01 continues in
effect pursuant to this subsection (b), EMED shall pay license fees as provided
in Section 2.02. Upon the effectiveness of any termination by EMED for breach
under Section 6.02(b), the license granted to AWARE under Article III shall
terminate.

     6.04. Additional Surviving Terms. All payment obligations accrued prior to
           --------------------------
any termination or expiration of this Agreement shall survive such termination
or expiration. All sublicenses granted to any end user in accordance with this
Agreement prior to any termination or expiration of this Agreement shall survive
such termination or expiration. If EMED holds a continuing license under this
Agreement, EMED shall also continue to have the rights set forth in Section 7.03
with respect to such license. The provisions of Sections 6.05, 7.02, 7.05, 7.06,
8.01, 8.02, 8.03 and 8.12 shall survive any termination or expiration of this
Agreement.

     6.05. Intellectual Property. AWARE and EMED shall negotiate in good faith
           ----------------------
for at least three months after effectiveness of expiration or termination of
this Agreement to reach agreement on specific definition of the intellectual
property owned by each party in accordance with the principles set forth in
Section 7.02. If, at any time after the end of such three month period, either
party shall determine in its judgment that negotiations are unlikely to result
in an acceptable outcome, such party may initiate arbitration to determine
ownership of intellectual

                            CONFIDENTIAL TREATMENT

                                       12
<PAGE>

property pursuant to the procedures specified in Section 8.01.

                           VII. INTELLECTUAL PROPERTY

  7.01. Software Licensing Procedures. (a) The procedures set forth in this
        ------------------------------
Section 67.01 shall govern the granting of sublicenses of software under this
Agreement.

     (b) Each of AWARE and EMED shall assign a unique number to each copy made
by it of Licensed Software or any other software provided to it by the other
party, whether for internal use or for sublicense to a user. Each of AWARE and
EMED shall keep full, clear and accurate records of all copies that it makes of
any such software and the identity and location of each third party to whom any
such software is provided. Each of EMED and AWARE may examine records of the
other party not more than once in any calendar quarter, during normal business
hours and upon reasonable notice.

     (c) Sublicenses of software granted under this Agreement shall include the
following provisions. Such terms may be set forth in a reasonably prominent
printed or electronic document that accompanies the software being sublicensed
and states that by use of such software, the user agrees to the terms set forth
in the document. Sublicenses may be granted directly, or by a reseller or other
intermediary. The provisions required by this subsection (c) are:

           (i) a provision restricting the sublicensee's use of the licensed
     software to its own business and professional purposes, provided that any
     sublicensee of a toolkit may use it to create new applications to be
     licensed to end users as part of the sublicensee's product;

           (ii) a provision requiring the sublicensee to take all reasonable
     precautions to keep the licensed software and any related documentation
     confidential;

           (iii) a provision prohibiting the sublicensee from reproducing
     (except for backup copies), reverse engineering, translating or creating
     other versions of the licensed software, provided that any sublicensee of a
     toolkit may use it to create new applications to

                            CONFIDENTIAL TREATMENT

                                       13
<PAGE>

     be licensed to end users as part of the sublicensee's product;

           (iv) a provision acknowledging that ownership of the licensed
     software remains exclusively with the grantor of the license or its
     suppliers;

           (v) a provision limiting the other party's liability to the
     sublicensee to at least the same extent that the liability of the grantor
     to the sublicensee is limited, and disclaiming warranties on behalf of the
     other party at least to the extent disclaimed on behalf of the grantor; and

           (vi) a provision stating that AWARE or EMED (as the case may be) is
     an intended third party beneficiary of the foregoing to the extent any
     materials or information delivered to the sublicensee originated with or
     are derived from materials or information supplied by AWARE or EMED (as the
     case may be), and shall have the right to enforce and shall be entitled to
     the benefit of any of the foregoing provisions as they relate to such
     materials or information.

Each party will use reasonable efforts to enforce license agreements executed by
its customers. In no event shall source code be released to any sublicensee.

  (d) Notwithstanding this Section 7.01 or any other provision of this
Agreement, software may be licensed to the Government of the United States of
America, or an agency or instrumentality thereof, under an agreement containing
software licensing terms generally used by the United States Government (or the
agency or instrumentality to which the software is licensed) for procurement of
commercial software.

     7.02. Ownership.  (a) As between EMED and AWARE, AWARE owns any software
           ---------
developed solely by AWARE or by any employee, consultant or other person acting
on AWARE's behalf (other than EMED) under this Agreement, including any
inventions, concepts, specifications, know-how and ideas embodied in such
software, together with all proprietary rights therein ("AWARE Intellectual
Property"). As between EMED and AWARE, EMED owns and shall continue to own those
concepts, specifications, know-how, and ideas

                            CONFIDENTIAL TREATMENT

                                       14
<PAGE>

embodied in the design and functionality of the Web Product and conceived solely
by EMED, and as applied in the Web Product for Medical Use, and any software
developed solely by EMED or by any employee, consultant or other person acting
on EMED's behalf (other than AWARE) under this Agreement, including any
inventions, concepts, specifications, know-how and ideas embodied in any of the
foregoing, together with all proprietary rights therein ("EMED Intellectual
Property"). As between EMED and AWARE, the parties shall jointly own any
software or other intellectual property jointly developed by the parties under
this Agreement and not allocated between them above, including any inventions,
concepts, specifications, know-how and ideas embodied therein, together with all
proprietary rights therein ("Joint Intellectual Property"). Whether or not any
intellectual property is jointly developed shall be determined in accordance
with United States patent or copyright law as applicable; provided that in no
event shall either party have an obligation to account to the other except as
specifically provided in this Agreement.

  (b) AWARE shall have the right to file and prosecute patent or copyright
applications on AWARE Intellectual Property and EMED shall have the right to
file and prosecute patent or copyright applications on EMED Intellectual
Property. The parties will cooperate in the filing and prosecution of patent or
copyright applications on Joint Intellectual Property, provided that neither
party shall file any such patent or copyright application without the prior
written consent of the other. Each party will cooperate with the other party in
the filing and prosecution by the other party of any patent or copyright
application that complies with this subsection (b), including by executing and
delivering or causing its officers and employees to execute and deliver (all at
the expense of the filing party) any documentation reasonably necessary or
appropriate for the filing and prosecution of such an application and the
vesting of rights as provided in this Agreement.

  (c) The exclusivity obligations of the parties under Article IV shall not in
any way be affected by the ownership of AWARE Intellectual Property, EMED
Intellectual Property, or Joint Intellectual Property as provided in this
Section 7.02, or by the filing of any patent or copyright application or the
grant or issuance of any

                            CONFIDENTIAL TREATMENT

                                       15
<PAGE>

patent or copyright. Neither party shall market, sell, license or distribute any
Joint Intellectual Property except to the extent that such Joint Intellectual
Property is covered by a license granted to such party hereunder.

  7.03 Source Code. Copies of source code of all Licensed Software will be made
       -----------
available to EMED by AWARE upon completion of each release or patch in which
such source code is included. The fact that AWARE has provided access to source
code shall in no way affect proprietary rights to source code or software, and
all source code shall continue to be owned by the party that owned it prior to
disclosure. All source code is "Confidential Information" as that term is used
in Section 7.06 and shall be subject to the restrictions set forth in Section
7.06. EMED will maintain source code revision control procedures with which both
AWARE and EMED will comply. These procedures will be designed to achieve, among
other things, compliance with "Good Manufacturing Practices" as defined by the
U.S. Food and Drug Administration and documentation of the ownership of source
code disclosed by either party. Provision of source code to EMED shall not
affect AWARE's obligations to provide engineering resources and support under
Section 5.01. Should AWARE wish to utilize its license rights pursuant to
Section 3.01, AWARE will notify EMED of such intentions and copies of source
code of Joint Products will be made available to AWARE by EMED upon completion
of each release or patch in which such source code is included. The fact that
EMED has provided access to source code shall in no way affect proprietary
rights to source code or software, and all source code shall continue to be
owned by the party that owned it prior to disclosure. All source code is
"Confidential Information" as that term is used in Section 7.06 and shall be
subject to the restrictions set forth in Section 7.06.

  7.04. Representations. (a) AWARE represents to EMED that AWARE has full
        ---------------
authority to enter into this Agreement and grant the licenses and rights set
forth herein.

  (b) EMED represents to AWARE that EMED has full authority to enter into this
Agreement and grant the licenses and rights set forth herein.

  7.05. Indemnities. (a) AWARE will, at its expense, defend against, hold EMED
        -----------
harmless from, and pay any final judgment against EMED or any customer of EMED
arising out

                            CONFIDENTIAL TREATMENT

                                       16
<PAGE>

of (x) any claim that  the Licensed Software infringed a copyright,
a patent or a trade secret of a third party, unless in the case of third party
patent claims, (i) AWARE can show that the patent claimed to have been infringed
was not known to Aware at the time of delivery to EMED of the infringing portion
of Licensed Software or (ii) such patent was infringed in order to comply with
an EMED design or specification or (iii)such patent would not be infringed by
the use of Licensed Software alone and not in combination with any EMED
software; or (y) out of marketing by AWARE of AWARE products (including any
product liability claim unless such product liability claim is caused by
designs, specifications or software provided by EMED); provided that (i) EMED
notifies AWARE in writing of such claim or action, and (ii) AWARE has sole
control of the defense and settlement of such claim or action.  In defending
against such claim or action to the extent it relates to software provided by
AWARE, AWARE may, at its option, agree to any settlement in which AWARE shall
either (1) procure for EMED and all customers of EMED the right to continue
using the software at issue; or (2) modify or replace such software so that it
no longer infringes, to the extent that the exercise of such option does not
result in a material adverse change in the operational characteristics of such
software, and equivalent functions and performance provided by AWARE remain
following implementation of such option.  If AWARE concludes in its judgment
that none of the foregoing options is reasonable, AWARE may remove the software
at issue and any other component supplied by AWARE rendered unusable as a result
of such removal and pay to EMED damages arising therefrom, including damages
incurred by reason of EMED's inability to perform its obligations under
sublicenses; provided that AWARE's liability for damages arising from such
inability shall be [*THE CONFIDENTIAL PORTION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

  (b) EMED will, at its expense, defend against, hold AWARE harmless from, and
pay any final judgment against AWARE or any customer of AWARE arising out of (x)
any claim that any software licensed to AWARE by EMED hereunder infringed a
copyright, a patent or a trade secret of a third party, unless in the case of
third party patent claims, (i) EMED can show that the patent claimed to have
been infringed was not known to EMED at the time of delivery to AWARE of the
infringing software or (ii) such patent was infringed in order to comply with an
AWARE

                            CONFIDENTIAL TREATMENT

                                       17
<PAGE>

design or specification or (iii) such patent would not be infringed by the use
of the software licensed by EMED alone and not in combination with any AWARE
software; or (y) out of marketing by EMED of EMED products (including any
product liability claim unless such product liability claim is caused by
designs, specifications or software provided by AWARE) provided that (i) AWARE
notifies EMED in writing of such claim or action, and (ii) EMED has sole control
of the defense and settlement of such claim or action. In defending against such
claim or action to the extent it relates to software provided by EMED, EMED may,
at its option, agree to any settlement in which EMED shall either (1) procure
for AWARE and all customers of AWARE the right to continue using the software at
issue; or (2) modify or replace such software so that it no longer infringes, to
the extent that the exercise of such option does not result in a material
adverse change in the operational characteristics of such software, and
equivalent functions and performance provided by EMED remain following
implementation of such option. If EMED concludes in its judgment that none of
the foregoing options is reasonable, EMED may remove the software at issue and
any other component supplied by EMED rendered unusable as a result of such
removal and pay to AWARE damages arising therefrom, including damages incurred
by reason of AWARE's inability to perform its obligations under sublicenses;
provided that EMED's liability for damages arising from such inability shall be
[*THE CONFIDENTIAL PORTION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION.]

  (c) If EMED shall determine in its judgment that the concepts, specifications,
know-how, and ideas embodied in the design and functionality of the Licensed
Software infringe or conflict with a patent or copyright not known to EMED on
the date of this Agreement, then EMED shall notify AWARE and the parties will
discuss in good faith whether the Licensed Software can be modified or other
steps may be taken to avoid such infringement. If EMED determines in its
judgment that no such modification or other steps can be reasonably implemented,
EMED may by notice terminate the obligations of AWARE and EMED under this
Agreement with respect to the affected portion of the Licensed Software, and the
indemnity of EMED in subsection (b) above shall apply only to those claims
relating to the affected portion of the Licensed Software of which AWARE or

                            CONFIDENTIAL TREATMENT

                                       18
<PAGE>

EMED had notice prior to the date of the first notice regarding infringement
delivered by EMED.

     7.06. Confidentiality. As used in this Agreement, "Confidential
           ---------------
Information" means (i) all confidential information, proprietary software, trade
secrets, know-how, and all other intellectual property that is subject to the
licenses granted in this Agreement and in which proprietary rights would be
adversely affected by disclosure and (ii) all other confidential or proprietary
information (including without limitation financial information and business
information such as customer lists) that is or has been disclosed by AWARE to
EMED or by EMED to AWARE. AWARE and EMED agree that they will not, and will not
permit their respective officers, employees, agents and representatives to,
without first obtaining the written consent of the other party, use, sell or
disclose any Confidential Information, except as expressly contemplated hereby
and except that Confidential Information may be disclosed by the party that owns
it unless such disclosure would adversely affect the proprietary nature of
Confidential Information subject to any of the licenses granted hereunder.
Either party may disclose Confidential Information to potential customers, and
to other third parties to the extent necessary to permit any such third party to
assist in manufacture or integration of the Web Product, provided that any such
potential customer or third party to whom Confidential Information is disclosed
shall execute a confidentiality agreement no less restrictive than this Section
7.06. "Confidential Information" does not include (i) information that is or
becomes (other than by disclosure in violation of this Agreement) generally
available to the public, (ii) information that the receiving party can show was
known to the receiving party prior to its disclosure by the other party, or
(iii) information required to be disclosed by law or regulation or by judicial
process or administrative order, provided that prompt notice and an opportunity
to seek a protective order is given to the other party prior to disclosure.
AWARE and EMED agree that this Agreement and the Schedules hereto are
Confidential Information subject to this Section 7.06. AWARE consents to the
disclosure of the relationship contemplated by this Agreement in filings by EMED
with the U.S. Securities and Exchange Commission and state securities
authorities, and the filing of this Agreement and the 1997 Agreement as related
exhibits; provided that EMED shall diligently seek confidential treatment of all

                            CONFIDENTIAL TREATMENT

                                       19
<PAGE>

pricing information and shall promptly deliver a copy of all such filings to
AWARE.

                                 VIII. GENERAL.

  8.01. Arbitration. Any controversy or claim arising out of or relating to this
        -----------
Agreement, or the breach thereof, shall be settled by arbitration administered
by the American Arbitration Association in Boston, Massachusetts under its
Commercial Arbitration Rules, and judgment on the award rendered by the
arbitrator(s) may be entered in any court having jurisdiction thereof.
Arbitration as specified in this Section 8.01 shall be the sole and exclusive
procedure for the resolution of disputes between the parties arising out of or
relating to this Agreement or the breach thereof; provided, however, that a
party, without prejudice to such procedure, may file a complaint to seek a
preliminary injunction or other provisional judicial relief, if in its judgment
such action is necessary to avoid irreparable damage or preserve the status quo.
Despite such action the parties will continue to participate in good faith in
the procedures specified in this Section 8.01. AWARE and EMED agree that any
breach of Sections 4.01, 4.02, 7.01 or 7.06 would cause irreparable harm and
that the aggrieved party shall be entitled to equitable relief in the nature of
an injunction for any such breach, without posting of a bond or other surety.

  8.02. Limitation of Warranties. THE OBLIGATIONS OF AWARE AND EMED EXPRESSLY
        -------------------------
STATED IN THIS AGREEMENT ARE IN LIEU OF ALL OTHER WARRANTIES OR CONDITIONS
EXPRESS OR IMPLIED.  TO THE EXTENT ALLOWABLE TO BY LAW, THIS EXCLUSION OF ALL
OTHER WARRANTIES AND CONDITIONS EXTENDS TO IMPLIED WARRANTIES OR CONDITIONS OF
MERCHANTABLE QUALITY AND FITNESS FOR A PARTICULAR PURPOSE, OR AGAINST
INFRINGEMENT AND THOSE ARISING BY STATUTE OR OTHERWISE IN LAW, OR FROM A COURSE
OF DEALING OR USAGE OF TRADE.

  8.03. Limitation of Liability. EMED AND AWARE AGREE THAT, EXCEPT AS EXPRESSLY
        ------------------------
STATED OTHERWISE IN SECTION 7.05.  THE LIABILITY OF EITHER OF THEM TO THE OTHER,
IF ANY, UNDER ANY THEORY OF LAW OR EQUITY, ARISING OUT OF, OR IN ANY WAY RELATED
TO THIS AGREEMENT OR THE FULFILLMENT OF ANY OF THE OBLIGATIONS OF EITHER OF THEM
UNDER THIS AGREEMENT, IS LIMITED TO MONEY DAMAGES NOT TO EXCEED THE TOTAL AMOUNT
PAID OR PAYABLE BY EMED TO AWARE UNDER THIS AGREEMENT.

                            CONFIDENTIAL TREATMENT

                                       20
<PAGE>

     8.04. Governing Law. This Agreement shall be governed by and construed in
           -------------
accordance with the laws of the Commonwealth of Massachusetts.

     8.05. Assignment.  (a) Subject to EMED's right to grant sublicenses
           ----------
hereunder, EMED may not assign this Agreement or any rights hereunder without
the prior written consent of AWARE, except that, without such consent and upon
notice to AWARE, (i) EMED may assign all of its rights hereunder to a
corporation or other legal entity that acquires substantially all of EMED's
assets or where EMED is consolidated or merged, but then only upon the express
assumption by such transferee or its successor of the obligations set forth in
this Agreement and (ii) EMED  may grant security interests in the rights of EMED
under this Agreement to secure the obligations of EMED to a bank or other
financial institution which has extended credit to EMED.

     (b) AWARE may not assign this Agreement or any rights hereunder without
the prior written consent of EMED, except that, without such consent and upon
notice to EMED, (i) AWARE may assign all of its rights hereunder to a
corporation or other legal entity that acquires substantially all of AWARE's
assets or where AWARE is consolidated or merged, but then only upon the express
assumption by such transferee or its successor of the obligations set forth in
this Agreement and (ii) AWARE may grant security interests in the rights of
AWARE under this Agreement to secure the obligations of AWARE to a bank or other
financial institution which has extended credit to AWARE.

     (c) This Agreement is binding upon, and inures to the benefit of, the
successors and permitted assigns of the parties.

     8.06. Effect of Waiver. The waiver or failure of either party to exercise
           ----------------
in any respect any right provided for in this Agreement shall not be deemed
a waiver of any further or future right hereunder.

                            CONFIDENTIAL TREATMENT

                                       21
<PAGE>

  8.07. Headings. The headings used in this Agreement are for convenience of
        --------
reference only and are not to be used in interpreting the provisions of this
Agreement.

  8.08. Complete Agreement. This Agreement is the exclusive statement of the
        ------------------
understanding between the parties with respect to its subject matter. It
supersedes all prior agreements, negotiations, representations and proposals,
written or oral, relating to the subject matter hereof.  No provisions of this
Agreement may be changed or modified except by an agreement in writing signed by
the party to be bound. No provision of any purchase order or other instrument
issued by EMED or any invoice or other form issued by AWARE that is inconsistent
with the provisions of this Agreement shall be binding or affect this Agreement
unless signed by both parties.

  8.09. Severability. If any provision of this Agreement is invalid or
        ------------
unenforceable in any particular case, such case shall not invalidate or render
unenforceable any other part of this Agreement. This Agreement shall be
construed as not containing the particular provision or provisions held to be
invalid or unenforceable to the extent of the particular case, and the rights
and obligations of the parties hereto shall be construed and enforced
accordingly.

  8.10. Effectiveness of Agreement; Counterparts. This Agreement is effective
        ----------------------------------------
when executed by both parties. This Agreement may be executed in counterparts,
each of which shall constitute one and the same instrument.

  8.11. Notices. All notices provided for in this Agreement shall be in writing
        -------
or facsimile, addressed to the appropriate party at the respective address set
forth below or to such other then-current address as is specified by notice, as
follows:

     to AWARE:

                      AWARE, Inc.
                      40 Middlesex Turnpike
                      Bedford, MA  01730
                      Facsimile:  (617) 276-4001
                      Attention:  Edmund Reiter

                            CONFIDENTIAL TREATMENT

                                       22
<PAGE>

     to EMED:

                      EMED Technologies Corporation
                      25 Hartwell Avenue
                      Lexington, MA  02421
                      Facsimile:  (781) 861-6360
                      Attention:  Howard Pinsky

Notices sent by certified mail, return receipt requested to the address
specified pursuant to this Section 7.11 shall be effective three business days
after deposit in the U.S. Mail with postage prepaid. Notice delivered by any
other means shall be effective upon receipt.

  7.12. No Agency. AWARE and EMED are independent contractors and separate legal
        ---------
entities and shall in no way be interpreted as partners, joint venturers,
agents, employees or legal representatives of each other for any purposes.
Neither party shall be responsible for or bound by any act of the other party or
the other party's agents, employees or any persons in any capacity in its
service.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the
first date set forth above.

EMED TECHNOLOGIES
CORPORATION                            AWARE, INC.

By: /s/Howard Pinsky                   By: /s/ Edmund C. Reiter
    -----------------                      --------------------
Name: Howard Pinsky                    Name: Edmund C. Reiter
Title: Chief Technology                Title: Senior Vice President
       Officer

                            CONFIDENTIAL TREATMENT

                                       23
<PAGE>

                                   Schedule 1

                           Description of Technology

     The Web Product accepts medical images, reports, and other information from
various sources, and makes them available for distribution over the web to thin
web clients.  Reports are collected and linked with the original studies
(images).  The Web Product includes the application defined by EMED, and user
interfaces, features, and web server technology developed by EMED which handles
the image, text, voice and administrative input required for systems operation.
The Web Product further includes HTML generation, web plug-in, compression, and
end-user application software, using core components developed and owned by
AWARE, Inc.  In addition, the product consists of user and technical
documentation which have been provided by both parties.

                            CONFIDENTIAL TREATMENT

                                       24<PAGE>

CONFIDENTIAL TREATMENT                                             EXHIBIT 10.22

                  SOFTWARE LICENSING AND DEVELOPMENT AGREEMENT

     This Software Licensing and Development Agreement is entered into as of May
30, 1997 (the "Effective Date") between AWARE, Inc. ("AWARE") and ACCESS
Radiology Corporation ("ACCESS").

                                  Background
                                  ----------

     1. ACCESS is in the business of providing integrated hardware and software
systems and services with respect to the transmission and interpretation of
medical images. AWARE develops and licenses proprietary computer software that
is useful for compression and web based viewing of digital images.

     2. ACCESS and AWARE are currently parties to a Software Supply Agreement
dated as of November 8, 1995 (the "Old Agreement") under which ACCESS has
licensed certain software from AWARE.

     3. ACCESS and AWARE wish to modify the terms of the Old Agreement with
respect to the software currently licensed to ACCESS, and to provide for the
development of new products as described below.

     NOW, THEREFORE, the parties agree as follows:

          I. LICENSING OF COMPRESSION SOFTWARE; PAYMENTS.

     1.01. Grant of Compression License. Subject to the terms of this Agreement,
           ----------------------------
AWARE grants to ACCESS the following rights, under any patent, copyright, trade
secret or other proprietary right of AWARE, whether presently held or hereafter
acquired, with respect to the proprietary image compression software identified
on Schedule I (the "Compression Software"). The rights granted to ACCESS shall
be exclusive to the extent set forth in Article II.

           (a) The right to use the Compression Software for ACCESS's internal
     business purposes and for the support of ACCESS customers, and to use and
     make available Compression Software, for integration solely with other
     components of ACCESS products provided to ACCESS customers and solely for

                           CONFIDENTIAL TREATMENT

                                      -1-
<PAGE>

     Medical Use. ACCESS shall not resell toolkits or other applications
     included in the Compression Software except to the extent integrated in
     other ACCESS products with substantial ACCESS content.

           (b) The right to grant sublicenses of the Compression Software for
     Medical Use, solely as integrated with ACCESS products, to users of ACCESS
     products. Sublicenses will be granted in compliance with the procedures set
     forth in Section 5.01.

For purposes of the Agreement, "Medical Use" means the compression,
transmission, viewing or other processing of medical images.

     1.02. Material Supplied for Compression Software. AWARE will make the
           ------------------------------------------
following materials available to ACCESS.

           (a) One copy of the latest object code or executable code for the
     Compression Software, with all upgrades as they are released. If the copy
     of the Compression Software initially provided is lost, damaged or
     destroyed, AWARE will provide at cost a replacement copy of the Compression
     Software, which may be a more recent release or version.

           (a) One copy of documentation in English and documentation updates as
     they are prepared and released which, when taken together, constitute
     complete documentation of the Compression Software. Additional copies of
     documentation may be purchased at AWARE's then-current purchase price.

     1.03. License Fees; Payments. (a) ACCESS shall prepay to AWARE a
           ----------------------
nonrefundable fee of [*THE CONFIDENTIAL PORTION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] on account of the
license and other rights granted to ACCESS hereunder (the "Prepayment"). The
Prepayment shall be due on August 30, 1997. The Prepayment shall bear interest
at the rate of 1% per month from August 30, 1997 if not paid on or before that
date.

(b)  [*THE CONFIDENTIAL PORTION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
     SECURITIES AND EXCHANGE COMMISSION.] of the Prepayment shall be applied to
     pay a [*THE CONFIDENTIAL PORTION HAS BEEN OMITTED AND FILED SEPARATELY WITH
     THE SECURITIES AND EXCHANGE COMMISSION.] AWARE acknowledges that ACCESS has
     [*THE CONFIDENTIAL PORTION HAS BEEN OMITTED AND FILED

                            CONFIDENTIAL TREATMENT

                                      -2-
<PAGE>

     SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] as of the date of
     this Agreement (the "Old Agreement Licenses"). [*THE CONFIDENTIAL PORTION
     HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
     COMMISSION.] of the Prepayment to license fees at the rate provided in this
     subsection, [*THE CONFIDENTIAL PORTION HAS BEEN OMITTED AND FILED
     SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] This pricing will
     apply to the Compression Software product identified in Schedule I, and not
     to the "Joint Product" developed pursuant to Article III.

     (c) Promptly after the end of each calendar quarter, ACCESS will deliver to
AWARE a statement setting forth, for such quarter, (i) the number of sublicenses
of Compression Software granted for compression of images, (ii) the utilization
of Old Agreement Licenses, (iii) the amount of the Prepayment applied against
license fees due and (iv) any balance of license fees due. After [*THE
CONFIDENTIAL PORTION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION.] of the Prepayment and the [*THE CONFIDENTIAL PORTION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION.] each quarterly statement shall be accompanied by payment of license
fees due. ACCESS will use its best efforts to provide such statement and pay
license fees due within 10 days of the end of each calendar quarter. Each
quarterly statement and payment of license fees shall be provided no later than
30 days after the end of the relevant calendar quarter.

     (d) ACCESS will keep complete books of account containing all
particulars that may be necessary to determine the amounts payable to AWARE
hereunder. Such books and supporting data shall be open for inspection for one
year following the calendar year to which they pertain, at reasonable times and
upon reasonable notice, by an independent auditor for purposes of verifying the
statements delivered pursuant to subsection (c) above. AWARE will not conduct
more than one such inspection for books and supporting data relating to any
single calendar year. The results of any inspection shall be made available to
ACCESS. If the agreed results of an inspection show an underpayment or
overpayment, then ACCESS shall pay to AWARE the amount of any underpayment and
AWARE shall pay to ACCESS the amount of any overpayment. If the agreed results
of such inspection show that ACCESS has underpaid AWARE by [*THE CONFIDENTIAL
PORTION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION.] or more, then ACCESS shall pay to AWARE the reasonable and
documented out of pocket costs of conducting such inspection, and allow
inspection of the books and supporting data

                            CONFIDENTIAL TREATMENT

                                      -3-
<PAGE>

for the prior two years. AWARE shall otherwise bear the costs it incurs in
performing any inspection.

     1.04. Support of Compression Software. (a) AWARE warrants to ACCESS that
           -------------------------------
the Compression Software will perform substantially in accordance with the
specifications included in Schedule I. AWARE will use its best efforts to ensure
such performance and, if necessary, to supply ACCESS with a corrected version of
the Compression Software as soon as practical after AWARE is notified of any
non-conformity. AWARE will provide maintenance releases, scheduled and
reasonable improvements in functionality, bug fixes and work-arounds at no
charge. This warranty will not apply to copies of Compression Software lost or
damaged through no fault of AWARE. AWARE will provide technical training to a
limited number of technically qualified ACCESS personnel without charge. ACCESS
and AWARE shall mutually agree upon a reasonable schedule for training of ACCESS
personnel.

     (b) As between ACCESS and AWARE, ACCESS shall be solely responsible for
installation of Compression Software at end user sites, integration of
Compression Software into devices sold or otherwise provided by ACCESS, and
support of ACCESS customers. The warranty and support obligations of AWARE under
subsection (a) above shall be limited to support and service provided directly
to ACCESS as contemplated by subsection (a).

                                II. EXCLUSIVITY

     2.01 Exclusivity Commitments. (a) The rights of ACCESS to use and
          -----------------------
sublicense software developed, owned or licensed by AWARE for Medical Use shall
be exclusive to the extent set forth herein. From the Effective Date until the
termination of exclusivity as provided herein, AWARE will not (except as
expressly permitted by this Agreement) supply for Medical Use or permit any
person to use for Medical Use (i) the Compression Software or any modification
or improvement of the Compression Software, (ii) any other software developed,
owned or licensed by AWARE that implements lossy compression of images, or (iii)
any other software developed, owned or licensed by AWARE that provides
functionality similar to the Joint Product contemplated by Article III. AWARE
will take reasonable steps to assure compliance with this exclusivity commitment
by third parties to whom AWARE provides software. Notwithstanding anything
contained in this Agreement, AWARE may provide its ADSL, SDSL, HFC and any other
general data communication product (not including lossy compression) to third
parties for Medical Use or any other purpose.

                            CONFIDENTIAL TREATMENT

                                      -4-
<PAGE>

     (b) From the Effective Date until the termination of exclusivity as
provided herein, AWARE will be the exclusive supplier to ACCESS of compression
and web based viewing software for use in ACCESS's current product line
(together with upgrades and new versions thereof) and the Joint Product
contemplated by Article III, and ACCESS will not purchase or license from any
other party compression software or web based viewing software for ACCESS's
current product line (together with upgrades and new versions thereof) or the
Joint Product contemplated by Article III.

     2.02. Exceptions. (a) Licenses of Compression Software for Medical Use
           ----------
which have been previously granted and for which all license fees have been
invoiced as of the date of this Agreement shall continue in effect
notwithstanding Section 2.01.

     (b) Notwithstanding Section 2.01, AWARE may grant licenses for Medical Use
of the current release of the Compression Software as described in Schedule I,
and may permit such customers to include copies of the Excepted Release in
equipment made available to end users.

AWARE shall not permit any customer to modify the Excepted Release (or any other
version of the Compression Software) for Medical Use and shall not make the
source code of the Excepted Release (or any other version of the Compression
Software) available to any third party.

     (c) AWARE may provide support for Compression Software that is permitted to
be licensed for Medical Use to the limited extent set forth in this subsection
(c). This support may be provided only to customers to whom licensing of
Compression Software for Medical Use is permitted by this Section 2.02. AWARE
may provide corrections of reported defects in the operation of the Excepted
Release with any versions of Netscape Navigator, Microsoft Internet Explorer,
MAC OS System 7, Windows 95 and Windows NT that are current as of the date of
this Agreement or are released within 18 months after the date of this
Agreement. AWARE will not modify the Excepted Release for the purpose of
enabling it to operate with any version of such browsers or operating systems
released later than 18 months after the date of this Agreement. As used in this
subsection (c), "defect" means a condition that causes run time errors or
incorrect results. ACCESS and AWARE may mutually agree to permit a greater level
of support for certain customers on a case by case basis, taking into account
the willingness of the customer involved to purchase products of the development
efforts contemplated by the Agreement, the level of resources required, and the
nature and business activities of the customer requesting support. Except as
expressly agreed in advance by ACCESS, AWARE will not make upgrades of the
Excepted

                            CONFIDENTIAL TREATMENT

                                      -5-
<PAGE>

Release available for Medical Use to anyone other than ACCESS and its
sublicensees.

     2.03. Transition. Promptly after the date of this Agreement, AWARE will
           ----------
publicly announce that it has entered into an exclusive relationship with ACCESS
and that ACCESS and AWARE are making a transition to the products contemplated
by the development provisions of this Agreement. This announcement will be
subject to review by ACCESS before its release.

                 III. DEVELOPMENT AND MARKETING OF NEW PRODUCTS

     3.01. Development Project. (a) Promptly upon execution of this Agreement,
           -------------------
AWARE and ACCESS will commence the joint development of a client/server product
that provides for wide-spread distribution and web based viewing of compressed
medical images, having substantially the functionality described in Schedule II.
Each of AWARE and ACCESS will use their best efforts to fulfill their respective
development responsibilities set forth in Schedule II on the timetable set forth
in Schedule II. Best efforts will include (without limitation) maintaining
staffing available for the development project consistent with the
responsibilities and timetable set forth in Schedule II. It is understood that
Schedule II is a planning document that is subject to change as development work
proceeds. AWARE and ACCESS will cooperate and consult in the development effort
and share information as necessary and appropriate for timely completion of the
development project. ACCESS will have final authority and responsibility for
decisions concerning design, specifications and development of the Joint
Product. The products, toolkits, concepts, inventions and applications arising
out of the development work conducted by ACCESS and AWARE under this Agreement,
including all software developed or contributed by either party, are
collectively referred to as the "Joint Product". Each party will bear expenses
it incurs in development of the Joint Product.

     (b) AWARE and ACCESS shall each have access to the source code of software
under development or included in the Joint Product. The fact that either AWARE
or ACCESS has provided access to source code shall in no way affect proprietary
rights to source code or software, and all source code shall continue to be
owned by the party that owned it prior to disclosure. All source code is
"Confidential Information" as that term is used in Section 5.06 and shall be
subject to the restrictions set forth in Section 5.06. ACCESS will maintain
source code revision control procedures with which both AWARE and ACCESS will
comply. These procedures will be designed to achieve, among other things,

                            CONFIDENTIAL TREATMENT

                                      -6-
<PAGE>

compliance with "Good Manufacturing Practices" as defined by the U.S. Food and
Drug Administration and documentation of the ownership of source code disclosed
by either party.

     3.02. Marketing; Licenses. ACCESS shall have following rights with respect
           -------------------
to the Joint Product under any patent, copyright, trade secret or other
proprietary right of AWARE, whether presently held or hereafter acquired, which
AWARE hereby grants to ACCESS. The rights granted to ACCESS shall be exclusive
to the extent set forth in Article II.

           (a) The right to use the Joint Product for internal purposes and in
     support of users of ACCESS products for Medical Use, and to use and make
     available the Joint Product as part of ACCESS's product line and for
     integration with other components of ACCESS products.

           (b) The right to make and have made, use and have used, and sell,
     lease or otherwise transfer the Joint Product, and to grant sublicenses of
     the software and other intellectual property included in the Joint Product,
     to users of ACCESS products for Medical Use in which such software is
     included. Users to whom sublicenses are granted may include original
     equipment manufacturers or other parties which utilize toolkits to create
     derivative products for Medical Use which will in turn be licensed to end
     users. Sublicenses of software will be granted in compliance with the
     procedures set forth in Section 5.01.

           (c) The right to modify the Joint Product and the software included
     in it to create new releases and new products for Medical Use, to make and
     have made, use and have used, and sell, lease or otherwise transfer
     products including modifications for Medical Use, and to grant sublicenses
     of software as modified to users of ACCESS products in which such software
     is included, in all cases for Medical Use. Users to whom sublicenses are
     granted may include original equipment manufacturers or other parties which
     utilize toolkits to create derivative products for Medical Use which will
     in turn be licensed to end users. Sublicenses of software will be granted
     in compliance with the procedures set forth in Section 5.01.

     3.03. Royalties. (a) In consideration of AWARE's contributions to the Joint
           ---------
Product, ACCESS will pay royalties to AWARE as determined pursuant to this
Section 3.03. Royalties payable to AWARE will be calculated as a percentage (the
"Royalty Percentage") of Net Software License Revenue. "Net Software License
Revenue" means amounts paid to ACCESS by customers for the Joint Product
(excluding taxes, shipping, insurance, the

                            CONFIDENTIAL TREATMENT

                                      -7-
<PAGE>

interest portion of payments under rental or leasing arrangements, actual
customer returns, customs duties, and any charges for services), reduced by (x)
costs of software that is obtained from third parties (other than AWARE) in bona
fide arms length negotiations and that ACCESS has determined in its judgment is
reasonably appropriate for inclusion in the Joint Product, (y) [*THE
CONFIDENTIAL PORTION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION.] of the costs of High End Storage and Network Hardware
and (z) [*THE CONFIDENTIAL PORTION HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION.] of the costs of all other hardware.
"High End Storage and Network Hardware" is defined in Schedule II.

     (b) The Royalty Percentage shall be a percentage of not less than [*THE
CONFIDENTIAL PORTION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION.] nor more than [*THE CONFIDENTIAL PORTION HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] which
shall reflect the contribution of AWARE to the development of the Joint Product,
and in particular the server software. Promptly upon completion of the
functional product descriptions and design specifications for the Joint Product,
AWARE and ACCESS will negotiate in good faith to reach agreement on the Royalty
Percentage.

     (c)  Promptly after the end of each calendar quarter after commencement of
marketing of the Joint Product, ACCESS will deliver to AWARE a statement setting
forth in reasonable detail the calculation of Net Software License Revenue and
royalties due. Each quarterly statement shall be accompanied by payment of
license fees due. ACCESS will use its best efforts to provide such statement
within 10 days of the end of each calendar quarter. Each quarterly statement and
payment of license fees shall be provided no later than 30 days after the end of
the relevant calendar quarter.

     (d) ACCESS will pay to AWARE, in addition to the royalties described in
subsection (a) above, a [*THE CONFIDENTIAL PORTION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] of Net Software License
Revenue [*THE CONFIDENTIAL PORTION HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION.] ACCESS will cooperate with AWARE in
marketing efforts and keep AWARE informed of market developments in general and
ACCESS marketing programs in particular.

     (e) No royalties shall be payable under this Section 3.03 for beta
testing installations, demonstration or loaner units. The duration of beta
testing will be limited to a period of time

                            CONFIDENTIAL TREATMENT

                                      -8-
<PAGE>

no longer than that which is determined by ACCESS to be reasonably necessary for
satisfaction of the requirements for commercial marketing of the product or
release being tested. Loaner units will be provided for a period of time no
longer than that which is reasonably necessary for the customer to assess the
functionality and desirability of the product or release being loaned. ACCESS
will not make the Joint Product available without charge except for the purposes
described in the preceding sentence and will not make the Joint Product
available without charge to assist in selling other products or in generating
revenues from other sources. ACCESS and AWARE will negotiate a reduced royalty
rate for users who migrate to the Joint Product after having previously
purchased ACCESS products including the Compression Software.

     3.04. Support. AWARE will have responsibilities for support of software
           -------
developed by AWARE and included in the Joint Product that are substantially
similar to AWARE's responsibilities for support of Compression Software pursuant
to Section 1.04. AWARE and ACCESS intend that ACCESS will pay support fees to
AWARE that represent a percentage equal to the Royalty Percentage of the
aggregate maintenance revenues received by ACCESS with respect to the Joint
Product. AWARE and ACCESS will negotiate in good faith to reach agreement on
calculation of support fees payable to AWARE at the same time that they
negotiate the Royalty Percentage.

     3.05. Marketing for Non-Medical Use. AWARE shall have the right to market
           -----------------------------
software and other components included in the Joint Product under any patent,
copyright, trade secret or other proprietary right of ACCESS, whether presently
held or hereafter acquired, for all uses other than medical uses. AWARE shall
have the following rights with respect to the Joint Product, which ACCESS hereby
grants to AWARE.

           (a) The right to use the Joint Product for internal purposes and in
     support of users of AWARE products, and to use and make available the Joint
     Product as part of AWARE's product line and for integration with other
     components of AWARE products, in all cases for uses other than Medical
     Uses. ACCESS agrees that "Medical Uses" for purposes of this Section 3.05
     does not include use by indemnity insurance companies and that AWARE may
     grant licenses to such companies; provided that no such license may permit
     the use of the Joint Product by a business unit of any such company that
     competes directly with ACCESS.

                            CONFIDENTIAL TREATMENT

                                      -9-
<PAGE>

          (b) The right to make and have made, use and have used, and sell,
     lease or otherwise transfer the Joint Product, and to grant sublicenses of
     the software and other intellectual property included in the Joint Product
     to users of AWARE products in which such software is included, in all cases
     for uses other than Medical Uses. Users to whom sublicenses are granted may
     include original equipment manufacturers or other parties which utilize
     toolkits to create derivative products for any use other than Medical Uses
     which will in turn be licensed to end users. Sublicenses of software will
     be granted in compliance with the procedures set forth in Section 5.01.

          (c) The right to modify the Joint Product and the software included in
     it to create new releases and new products, to make and have made, use and
     have used, and sell, lease or otherwise transfer products including
     modifications, and to grant sublicenses of software as modified to users of
     AWARE products in which such software is included, in all cases for uses
     other than Medical Uses. Users to whom sublicenses are granted may include
     original equipment manufacturers or other parties which utilize toolkits to
     create derivative products for any use other than Medical Uses which will
     in turn be licensed to end users. Sublicenses of software will be granted
     in compliance with the procedures set forth in Section 5.01.

AWARE shall pay royalties to ACCESS for licenses granted under this Section 3.05
in amounts to be agreed between ACCESS and AWARE. Except as agreed in writing
with ACCESS, AWARE will not make the Joint Product available without
charge.

                       IV. TERM OF RIGHTS AND OBLIGATIONS

     4.01. Term of Exclusivity. (a) The exclusivity provisions of Article II and
           -------------------
the other obligations of the parties under this Agreement shall remain in effect
unless and until terminated in accordance with this Article IV.

     (b) Subject to subsection (d) below, the exclusivity obligations of AWARE
and ACCESS will terminate on December 31, 1998 if AWARE has not received, on or
before that date, aggregate payments from ACCESS of at least [*THE CONFIDENTIAL
PORTION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION.] At least [*THE CONFIDENTIAL PORTION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] of such amount must

                            CONFIDENTIAL TREATMENT

                                      -10-
<PAGE>

consist of royalties and fees for the Joint Product, license fees for
Compression Software, or software maintenance revenues. The Prepayment will not
be counted towards this [*THE CONFIDENTIAL PORTION HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.] minimum.

     (c) Subject to subsection (d) below, the exclusivity obligations of AWARE
and ACCESS will terminate on December 31 of any year after 1998 if AWARE has not
received aggregate payments from ACCESS of at least [*THE CONFIDENTIAL PORTION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION.] during the year ended on that date. This entire amount must consist
of royalties and fees for the Joint Product, license fees for Compression
Software in excess of the portion of the Prepayment applied thereto, or software
maintenance revenues.

     (d) The dates set forth in subsections (b) and (c) above shall be extended
for a number of months (not exceeding twelve months) equal to the number of
whole months elapsed between December 31, 1997 and the date of a commercial
release of version 1.0 of the Joint Product that has been produced in compliance
with "good manufacturing practices" as defined by the U.S. Food and Drug
Administration (the "FDA"), and has received clearance for commercial marketing
for medical use from the FDA. This extension shall be effective if and only if
ACCESS shall have pursued clearance by the FDA and performance of ACCESS's
development responsibilities diligently and in good faith.

     4.02. Effect of Termination of Exclusivity or Expiration of Initial Term.
           ------------------------------------------------------------------
(a) If the exclusivity obligations of AWARE and ACCESS shall terminate pursuant
to Section 4.01, AWARE and ACCESS will discuss in good faith whether an
extension of exclusivity or other modifications to this Agreement may be
appropriate. Unless otherwise agreed in writing, upon termination of exclusivity
pursuant to Section 4.01, the licenses granted in Sections 1.01, 3.02 and 3.05
shall remain in effect until five years from the date of termination of
exclusivity, except that (i) the licenses granted to ACCESS shall be modified so
that they shall no longer be exclusive, and (ii) the license granted to AWARE
shall be modified so that it shall no longer be limited to non-Medical Uses. If
development of the Joint Product has not been completed at the time of
termination of exclusivity pursuant to Section 4.01, then rights under such
licenses shall apply to such portions of the Joint Product as shall be in
existence on the

                            CONFIDENTIAL TREATMENT

                                      -11-
<PAGE>

date of termination (including any applications that are incomplete).

     (b) AWARE and ACCESS agree that the royalties and license fees payable
under this Agreement shall be modified effective upon modification of the
licenses granted hereunder pursuant to subsection (a) above. AWARE and ACCESS
further agree that the appropriate amount of such modified royalties and license
fees cannot be determined as of the date of this Agreement. AWARE and ACCESS
shall negotiate in good faith for at least three months after effectiveness of
license modifications pursuant to subsection (a) to reach agreement on modified
license fees and royalties. If, at any time after the end of such three month
period, either party shall determine in its judgment that negotiations are
unlikely to result in an acceptable outcome, such party may initiate arbitration
to determine modified fees and royalties pursuant to the procedures specified in
Section 6.02.

     4.03. Termination for Breach. (a) If ACCESS shall materially breach its
           ----------------------
obligations under this Agreement, and such material breach shall be continuing
for at least 60 days after delivery of a notice by AWARE describing such breach,
then AWARE may by a separate notice terminate this Agreement for breach under
this Section 4.03(a).

     (b) If AWARE shall materially breach its obligations under this Agreement,
and such material breach shall be continuing for at least 60 days after delivery
of a notice by ACCESS describing such breach, then ACCESS may by a separate
notice terminate this Agreement for breach under this Section 4.03(b).

     (c) With respect to the obligations of AWARE and ACCESS to participate in
development of the Joint Product pursuant to Section 3.01(a), "material breach"
means willful failure of a party to devote best efforts to the development
project or to allocate sufficient resources to perform such party's
responsibilities.

     (d) Termination for breach under this Section 4.03 shall not be an
exclusive remedy, but shall be in addition to any other remedies that either
party may have.

     4.04. Effect of Termination for Breach. (a) If AWARE shall terminate this
           --------------------------------
agreement for breach pursuant to Section 4.03, then (i) the licenses granted to
ACCESS pursuant to Sections 1.01 and 3.02 shall immediately terminate and ACCESS
shall cease using or marketing the Compression Software and the Joint Product
and (ii) the license granted to AWARE pursuant to Section 3.05 shall remain in
effect.

                            CONFIDENTIAL TREATMENT

                                      -12-
<PAGE>

     (b) If ACCESS shall terminate this agreement for breach pursuant to Section
4.04, then (i) the license granted to AWARE pursuant to Section 3.05 shall
immediately terminate, and AWARE shall cease using or marketing the Joint
Product  (ii) the licenses granted to ACCESS pursuant to Sections 1.01 and 3.02
shall remain in effect and (iii) the exclusivity obligations of ACCESS under
Article II shall immediately terminate.

     (c) If development of the Joint Product has not been completed at the
time of termination for breach pursuant to Section 4.03, then rights under
continuing licenses shall apply to such portions of the Joint Product as shall
be in existence on the date of termination (including any applications that are
incomplete).

     (d) For so long as the license granted under Section 1.01 continues in
effect, ACCESS shall pay royalties as provided in Section 1.03. To the extent
that licenses of the Joint Product under Sections 3.02 and 3.05 remain in
effect, royalties payable with respect to the Joint Product will be determined
by agreement between the parties or, failing such agreement, by arbitration
under Section 6.02.

     4.06. Additional Surviving Terms. All payment obligations accrued
           --------------------------
prior to any termination shall survive such termination. All sublicenses granted
to any end user by either party in accordance with this Agreement prior to any
termination of this Agreement shall survive such termination. Either party which
holds a continuing license under this Agreement shall also continue to have the
rights set forth in Sections 1.02, 1.04. 3.01(b) and 3.04 with respect to such
license. The provisions of Sections 5.02, 5.03, 5.06, 6.02, 6.04, 6.05 and 6.14
shall survive any termination of this Agreement.

                            V. INTELLECTUAL PROPERTY

     5.01. Software Licensing Procedures. (a) The procedures set forth in
           -----------------------------
this Section 5.01 shall govern the granting of sublicenses of software to users
under this Agreement. In this Section 5.01, the party granting a sublicense to a
user is referred to as the "Licensor".

     (b) Each of AWARE and ACCESS shall assign a unique number to each copy made
by it of software comprising the Joint Product or any other software developed
or provided by the other party, whether for internal use or for sublicense to a
user.  Each of AWARE and ACCESS shall keep full, clear and accurate records of

                            CONFIDENTIAL TREATMENT

                                      -13-
<PAGE>

all copies that it makes of any such software and the identity and location of
each third party user to whom any such software is provided. Each of ACCESS and
AWARE may examine records of the other party not more than once in any calendar
quarter, during normal business hours and upon reasonable notice.

     (c) Upon granting a sublicense of software comprising the Joint Product or
any other software developed or provided by the other party, the Licensor shall
require that the user execute an agreement including the software licensing
terms set forth below. Such agreement may be between the user and the Licensor,
or between the user and a reseller or other intermediary authorized by the
Licensor.

           (i)   a provision restricting the sublicensee's use of the licensed
     software to its own business and professional purposes, provided that any
     sublicensee of a toolkit may use it to create new applications to be
     licensed to end users as part of the sublicensee's product;

           (ii)  a provision requiring the sublicensee to take all reasonable
     precautions to keep the licensed software and any related documentation
     confidential;

           (iii) a provision prohibiting the sublicensee from reproducing
     (except for backup copies), reverse engineering, translating or creating
     other versions of the licensed software, provided that any sublicensee of a
     toolkit may use it to create new applications to be licensed to end users
     as part of the sublicensee's product;

           (iv)  a provision acknowledging that ownership of the licensed
     software remains exclusively with the Licensor or its suppliers; and

           (v)   a provision limiting the other party's liability to the
     sublicensee to at least the same extent that the liability of the Licensor
     to the sublicensee is limited, and disclaiming warranties on behalf of the
     other party at least to the extent disclaimed on behalf of the Licensor.

Each party will use reasonable efforts to enforce license agreements executed by
its customers. AWARE agrees that any license of Compression Software granted by
ACCESS prior to the Effective Date need not be altered if it complied with the
requirements of the Old Agreement.

     (d) Notwithstanding this Section 5.01 or any other provision of this
Agreement, software may be licensed to the Government of the United States of
America, or an agency or instrumentality

                            CONFIDENTIAL TREATMENT

                                      -14-
<PAGE>

thereof, under an agreement containing software licensing terms generally used
by the United States Government (or the agency or instrumentality to which the
software is licensed) for procurement of commercial software.

     5.02. Ownership.  (a) As between ACCESS and AWARE, AWARE owns and shall
           ---------
continue to own the Compression Software (including without limitation AWARE's
AccuRad product) and any other software developed solely by AWARE or by any
employee, consultant or other person acting on AWARE's behalf under this
Agreement, including any inventions, concepts, specifications, know-how and
ideas embodied in such software, together with all proprietary rights therein
("AWARE Intellectual Property"). As between ACCESS and AWARE, ACCESS owns and
shall continue to own the concepts, specifications, know-how, and ideas embodied
in the design and functionality of the Joint Product, and as applied in the
Joint Product for Medical Use, and any  software developed solely by ACCESS or
by any employee, consultant or other person acting on ACCESS's behalf under this
Agreement, including any inventions, concepts, specifications, know-how and
ideas embodied in any of the foregoing, together with all proprietary rights
therein ("ACCESS Intellectual Property"). As between ACCESS and AWARE, the
parties shall jointly own any software or other intellectual property jointly
developed by the parties under this Agreement and not allocated between them
above, including any inventions, concepts, specifications, know-how and ideas
embodied therein, together with all proprietary rights therein ("Joint
Intellectual Property"). Whether or not any intellectual property is jointly
developed shall be determined in accordance with the United States patent laws.

     (b) AWARE shall have the right to file and prosecute patent or copyright
applications on AWARE Intellectual Property and ACCESS shall have the right to
file and prosecute patent or copyright applications on ACCESS Intellectual
Property. The parties will cooperate in the filing and prosecution of patent or
copyright applications on Joint Intellectual Property, provided that neither
party shall file any such patent or copyright application without the prior
written consent of the other. Each party will cooperate with the other party in
the filing and prosecution by the other party of any patent or copyright
application that complies with this subsection (b), including by executing and
delivering or causing its officers and employees to execute and deliver (all at
the expense of the filing party) any documentation reasonably necessary or
appropriate for the filing and prosecution of such an application and the
vesting of rights as provided in this Agreement.

     (c) The exclusivity obligations of the parties under Article II shall not
in any way be affected by the ownership of AWARE

                            CONFIDENTIAL TREATMENT

                                      -15-
<PAGE>

Intellectual Property, ACCESS Intellectual Property, or Joint Intellectual
Property as provided in this Section 5.02, or by the filing of any patent or
copyright application or the grant or issuance of any patent or copyright.
Neither party shall market, sell, license or distribute any Joint Intellectual
Property except to the extent that such Joint Intellectual Property is covered
by a license granted to such party hereunder.

     5.03. Trademarks. (a) The terms specified in Schedule 5.03 to this
           ----------
Agreement are trademarks or tradenames owned by AWARE and may not be used
without specific written permission. Nothing herein shall confer upon ACCESS any
proprietary interest in the trademarks or tradenames, except the right to use
the same in accordance with the terms hereof. All use of such marks or names,
and the goodwill associated therewith, shall inure to the benefit of AWARE.
ACCESS agrees not to, at any time during the term of this Agreement or
thereafter, directly or indirectly (i) dispute or contest the validity or
enforceability of AWARE's trademarks or tradenames, or (ii) take any action that
would dilute the value of the goodwill attaching to the trademarks or
tradenames.

     (b) ACCESS shall exclusively own the trademarks or trade names under which
the Joint Product is sold for Medical Use or otherwise provided by ACCESS, and
may file and prosecute trademark applications on such trademarks and tradenames.
AWARE agrees not to, at any time during the term of this Agreement or
thereafter, directly or indirectly dispute or contest the validity or
enforceability of such trademarks or tradenames.

     5.04. Representations. (a) AWARE represents to ACCESS that:
           ----------------

           (i)   AWARE has full authority to enter into this Agreement and grant
     the licenses and rights set forth herein.

           (ii)  To the best of AWARE's knowledge, the documentation and code of
     the Compression Software have not been published under circumstances which
     have caused loss of proprietary rights therein, and to the best of AWARE's
     knowledge, the documentation and code of the Compression Software do not
     infringe upon any patent, copyright or other proprietary right of any third
     party.

           (iii) AWARE is not aware of any claim of infringement of any patent,
     copyright or other proprietary right having been made or pending against
     AWARE relative to the documentation or code of the Compression Software.

     (b) ACCESS represents to AWARE that:

                            CONFIDENTIAL TREATMENT

                                      -16-
<PAGE>

           (i)   ACCESS has full authority to enter into this Agreement and
     grant the licenses and rights set forth herein.

           (ii)  To the best of ACCESS's knowledge, the specifications and
     functionality of the Joint Product, as set forth in Schedule II, do not
     infringe upon any patent, copyright or other proprietary right of any third
     party.

     5.05. Indemnities. (a) AWARE will, at its expense, defend against, hold
           -----------
ACCESS harmless from, and pay any final judgment against ACCESS or any customer
of ACCESS arising (x) out of any claim that AWARE Intellectual Property
infringed a copyright, a patent or a trade secret or (y) out of marketing by
AWARE of AWARE products (including any product liability claim unless such
product liability claim is caused by designs, specifications or software
provided by ACCESS); provided that (i) ACCESS notifies AWARE in writing of such
claim or action, and (ii) AWARE has sole control of the defense and settlement
of such claim or action. In defending against such claim or action to the extent
it relates to software provided by AWARE, AWARE may, at its option, agree to any
settlement in which AWARE shall either (1) procure for ACCESS and all customers
of ACCESS the right to continue using the software at issue; or (2) modify or
replace such software so that it no longer infringes, to the extent that the
exercise of such option does not result in a material adverse change in the
operational characteristics of such software, and equivalent functions and
performance provided by AWARE remain following implementation of such option. If
AWARE concludes in its judgment that none of the foregoing options is
reasonable, AWARE may remove the software at issue and any other component
supplied by AWARE rendered unusable as a result of such removal and pay to
ACCESS damages arising therefrom, including damages incurred by reason of
ACCESS's inability to perform its obligations under sublicenses; provided that
AWARE's liability for damages arising from such inability shall be [*THE
CONFIDENTIAL PORTION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION.]

     (b) ACCESS will, at its expense, defend against, hold ACCESS harmless from,
and pay any final judgment against AWARE or any customer of AWARE arising out of
(x) any claim that ACCESS Intellectual Property  infringed a copyright, a patent
or a trade secret or (y) out of marketing by ACCESS of ACCESS products
(including any product liability claim unless such product liability claim is
caused by designs, specifications or software provided by AWARE) provided that
(i) AWARE notifies ACCESS in writing of such claim or action, and (ii) ACCESS
has sole control of the defense and settlement of such claim or action.  In

                            CONFIDENTIAL TREATMENT

                                      -17-
<PAGE>

defending against such claim or action to the extent it relates to software
provided by ACCESS, ACCESS may, at its option, agree to any settlement in which
ACCESS shall either (1) procure for AWARE and all customers of AWARE the right
to continue using the software at issue; or (2) modify or replace such software
so that it no longer infringes, to the extent that the exercise of such option
does not result in a material adverse change in the operational characteristics
of such software, and equivalent functions and performance provided by ACCESS
remain following implementation of such option.  If ACCESS concludes in its
judgment that none of the foregoing options is reasonable, ACCESS may remove the
software at issue and any other component supplied by ACCESS rendered unusable
as a result of such removal and pay to AWARE damages arising therefrom,
including damages incurred by reason of AWARE's inability to perform its
obligations under sublicenses; provided that ACCESS's liability for damages
arising from such inability shall be [*THE CONFIDENTIAL PORTION HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

     (c) If ACCESS shall determine in its judgment that the concepts,
specifications, know-how, and ideas embodied in the design and functionality of
the Joint Product infringe or conflict with a patent, copyright, trade secret or
other proprietary right not known to ACCESS on the date of this Agreement, then
ACCESS shall notify AWARE and the parties will discuss in good faith whether the
Joint Product can be modified or other  steps may be taken to avoid such
infringement. If ACCESS determines in its judgment that no such modification or
other steps can be reasonably implemented, ACCESS may by notice terminate the
obligations of AWARE and ACCESS under this Agreement with respect to the Joint
Product, and the indemnity of ACCESS in subsection (b) above shall apply only to
those claims relating to the Joint Product of which AWARE or ACCESS had notice
prior to the date of the first notice regarding infringement delivered by
ACCESS.

     5.06. Confidentiality. As used in this Agreement, "Confidential
           ---------------
Information" means (i) all confidential information, proprietary software, trade
secrets, know-how, and all other intellectual property that is subject to the
licenses granted in this Agreement and in which proprietary rights would be
adversely affected by disclosure and (ii) all other confidential or proprietary
information (including without limitation financial information and business
information such as customer lists) that is or has been disclosed by AWARE to
ACCESS or by ACCESS to AWARE. AWARE and ACCESS agree that they will not, and
will not permit their respective officers, employees, agents and representatives
to, without first obtaining the written consent of the other party, use, sell or
disclose any

                            CONFIDENTIAL TREATMENT

                                      -18-
<PAGE>

Confidential Information, except as expressly contemplated hereby and except
that Confidential Information may be disclosed by the party that owns it unless
such disclosure would adversely affect the proprietary nature of Confidential
Information subject to any of the licenses granted hereunder. Either party may
disclose Confidential Information to potential customers, and to other third
parties to the extent necessary to permit any such third party to assist in
manufacture or integration of the Joint Product, provided that any such
potential customer or third party to whom Confidential Information is disclosed
shall execute a confidentiality agreement no less restrictive than this Section
5.06. "Confidential Information" does not include (i) information that is or
becomes (other than by disclosure in violation of this Agreement) generally
available to the public, (ii) information that the receiving party can show was
known to the receiving party prior to its disclosure by the other party, or
(iii) information required to be disclosed by law or regulation or by judicial
process or administrative order, provided that prompt notice and an opportunity
to seek a protective order is given to the other party prior to disclosure.
AWARE and ACCESS agree that this Agreement and the Schedules thereto are
Confidential Information subject to this Section 5.06.

                                  VI. GENERAL.

     6.01. Regulatory Matters. ACCESS shall make and prosecute all filings and
           ------------------
take such other actions as ACCESS shall consider appropriate to obtain clearance
for commercial marketing of the Joint Products from the FDA and such other
authorities as may be appropriate for marketing of the Joint Product. AWARE will
cooperate with ACCESS in providing information and assistance with respect to
such filings and other actions and may review and comment on filings made by
ACCESS. AWARE shall take such actions to comply with regulatory requirements
(including without limitation "good manufacturing practices" as defined by the
FDA, and standards and procedures specified in filings made with the FDA) as
ACCESS shall reasonably request, including without limitation use of identified
development, design and specification methodologies.

     6.02. Arbitration. Any controversy or claim arising out of or relating to
           -----------
this Agreement, or the breach thereof, shall be settled by arbitration
administered by the American Arbitration Association in Boston, Massachusetts
under its Commercial Arbitration Rules, and judgment on the award rendered by
the arbitrator(s) may be entered in any court having jurisdiction thereof.
Arbitration as specified in this Section 6.02 shall be the sole and exclusive
procedure for the resolution of disputes

                            CONFIDENTIAL TREATMENT

                                      -19-
<PAGE>

between the parties arising out of or relating to this Agreement or the breach
thereof; provided, however, that a party, without prejudice to such procedure,
may file a complaint to seek a preliminary injunction or other provisional
judicial relief, if in its judgment such action is necessary to avoid
irreparable damage or preserve the status quo. Despite such action the parties
will continue to participate in good faith in the procedures specified in this
Section 6.02. AWARE and ACCESS agree that any breach of Sections 2.01, 2.02,
4.04, 5.01, 5.03 or 5.06 would cause irreparable harm and that the aggrieved
party shall be entitled to equitable relief in the nature of an injunction for
any such breach, without posting of a bond or other surety.

     6.03. Public Announcements. AWARE and ACCESS will cooperate in all public
           --------------------
disclosure concerning this agreement, and neither party shall make any such
disclosure without the approval of the other. Approval of disclosure required by
law or regulation shall not be unreasonably withheld; provided that it may be a
condition of such approval that the party making such disclosure seek
confidential treatment.

     6.04. Limitation of Warranties. THE OBLIGATIONS OF AWARE AND ACCESS
           ------------------------
EXPRESSLY STATED IN THIS AGREEMENT ARE IN LIEU OF ALL OTHER WARRANTIES OR
CONDITIONS EXPRESS OR IMPLIED. TO THE EXTENT ALLOWABLE TO BY LAW, THIS EXCLUSION
OF ALL OTHER WARRANTIES AND CONDITIONS EXTENDS TO IMPLIED WARRANTIES OR
CONDITIONS OF MERCHANTABLE QUALITY AND FITNESS FOR A PARTICULAR PURPOSE, AND
THOSE ARISING BY STATUTE OR OTHERWISE IN LAW, OR FROM A COURSE OF DEALING OR
USAGE OF TRADE.

     6.05. Limitation of Liability. ACCESS AND AWARE AGREE THAT, EXCEPT AS
           -----------------------
EXPRESSLY STATED OTHERWISE IN THIS AGREEMENT, THE LIABILITY OF EITHER OF THEM TO
THE OTHER, IF ANY, UNDER ANY THEORY OF LAW OR EQUITY, ARISING OUT OF, OR IN ANY
WAY RELATED TO THIS AGREEMENT OR THE FULFILLMENT OF ANY OF THE OBLIGATIONS OF
EITHER OF THEM UNDER THIS AGREEMENT, IS LIMITED TO MONEY DAMAGES NOT TO EXCEED
THE TOTAL AMOUNT PAID OR PAYABLE BY ACCESS TO AWARE OR BY AWARE TO ACCESS (AS
THE CASE MAY BE) UNDER THIS AGREEMENT.

     6.06. Governing Law. This Agreement shall be governed by and construed in
           -------------
accordance with the laws of the Commonwealth of Massachusetts.

     6.07. Assignment.  (a) Subject to ACCESS's right to grant sublicenses
           ----------
hereunder, ACCESS may not assign this Agreement or any rights hereunder without
the prior written consent of AWARE, except that, without such consent and upon
notice to AWARE, (i) ACCESS may assign all of its rights hereunder to a
corporation or other legal entity that acquires substantially all of ACCESS's
assets or where ACCESS is consolidated or merged, but then only

                            CONFIDENTIAL TREATMENT

                                      -20-
<PAGE>

upon the express assumption by such transferee or its successor of the
obligations set forth in this Agreement and (ii) ACCESS may grant security
interests in the rights of ACCESS under this Agreement to secure the obligations
of ACCESS to a bank or other financial institution which has extended credit to
ACCESS.

     (b)  Subject to AWARE's right to grant sublicenses hereunder, AWARE may not
assign this Agreement or any rights hereunder without the prior written consent
of ACCESS, except that, without such consent and upon notice to ACCESS, (i)
AWARE may assign all of its rights hereunder to a corporation or other legal
entity that acquires substantially all of AWARE's assets or where AWARE is
consolidated or merged, but then only upon the express assumption by such
transferee or its successor of the obligations set forth in this Agreement and
(ii) AWARE may grant security interests in the rights of AWARE under this
Agreement to secure the obligations of AWARE to a bank or other financial
institution which has extended credit to AWARE.

     (c) This Agreement is binding upon, and inures to the benefit of, the
successors and permitted assigns of the parties.

     6.08. Effect of Waiver. The waiver or failure of either party to exercise
           ----------------
in any respect any right provided for in this Agreement shall not be deemed a
waiver of any further or future right hereunder.

     6.09. Headings. The headings used in this Agreement are for convenience of
           --------
reference only and are not to be used in interpreting the provisions of this
Agreement.

     6.10. Complete Agreement. This Agreement is the exclusive statement of the
           ------------------
understanding between the parties with respect to its subject matter. It
supersedes all prior agreements, negotiations, representations and proposals,
written or oral, relating to the subject matter hereof, including without
limitation the Old Agreement.  No provisions of this Agreement may be changed or
modified except by an agreement in writing signed by the party to be bound. No
provision of any purchase order or other instrument issued by ACCESS or any
invoice or other form issued by AWARE that is inconsistent with the provisions
of this Agreement shall be binding or affect this Agreement unless signed by
both parties.

     6.11. Severability. If any provision of this Agreement is invalid or
           ------------
unenforceable in any particular case, such case shall not invalidate or render
unenforceable any other part of this Agreement. This Agreement shall be
construed as not containing the particular provision or provisions held to be
invalid or unenforceable to the extent of the particular case, and the

                            CONFIDENTIAL TREATMENT

                                      -21-
<PAGE>

rights and obligations of the parties hereto shall be construed and enforced
accordingly.

     6.12. Effectiveness of Agreement; Counterparts. This Agreement is effective
           ----------------------------------------
when executed by both parties. This Agreement may be executed in counterparts,
each of which shall constitute one and the same instrument.

     6.13. Notices. All notices provided for in this Agreement shall be in
           -------
writing or facsimile, addressed to the appropriate party at the respective
address set forth below or to such other then-current address as is specified by
notice, as follows:

     (b)      to AWARE:

                   Aware, Inc.
                   One Oak Park
                   Bedford, MA  01730
                   Facsimile:  (617) 276-4001
                   Attention:  Edmund Reiter

     (c)      to ACCESS:

                   ACCESS Radiology Corporation
                   313 Speen Street
                   Natick, MA  01760
                   Facsimile:  (508) 647-9350
                   Attention:  Howard Pinsky

                            CONFIDENTIAL TREATMENT

                                      -22-
<PAGE>

Notices sent by certified mail, return receipt requested to the address
specified pursuant to this Section 6.13 shall be effective three business days
after deposit in the U.S. Mail with postage prepaid. Notice delivered by any
other means shall be effective upon receipt.

     6.14. No Agency. AWARE and ACCESS are independent contractors and separate
           ---------
legal entities and shall in no way be interpreted as partners, joint venturers,
agents, employees or legal representatives of each other for any purposes.
Neither party shall be responsible for or bound by any act of the other party or
the other party's agents, employees or any persons in any capacity in its
service.

           IN WITNESS WHEREOF, the parties hereto have executed this Agreement
as of the first date set forth above.

ACCESS RADIOLOGY
CORPORATION                         AWARE, INC.

By: /s/ Howard Pinsky               By: /s/ Edmund C. Reiter
    -----------------                   --------------------
Name: Howard Pinsky                 Name: Edmund C. Reiter
Title: Vice President of            Title: Senior Vice President
       Technology

                            CONFIDENTIAL TREATMENT

                                      -23-
<PAGE>

                                  Schedule 1

1.  Existing Accurad Product and Plugin Specifications
    --------------------------------------------------

    1.a  AccuPress for Radiology Version 3.6 for Unix and DOS User's Guide and
         Developer's Kit
    1.b  AWARE AccuRad Plugin User's Guide:  Plugin revision history
    1.c  AWARE AccuRad Plugin User's Guide:  Embed Options Reference
    1.d  AWARE AccuRad Plugin User's Guide:  Using the Plugin

2.  Agreed to Supported AWARE Customer List
    ---------------------------------------

    [*THE CONFIDENTIAL PORTION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION.]

                            CONFIDENTIAL TREATMENT

                                      -24-
<PAGE>

                                  SCHEDULE 2

Summary of Project "Butterfly"

Joint software development resulting in a client/server product that provides
for wide-spread distribution and web-based viewing and editing of compressed
medical images.  The Product is intended to be marketable on a world-wide basis
to a broad OEM and direct user base assuming no prior and perhaps no potential
future ACCESS content.  The product is intended to draw from the core
competencies from both organizations; wavelet (and other algorithms as
appropriate) compression and web image processing from AWARE, and general
medical market imaging knowledge and Compression Server development from ACCESS.
ACCESS and AWARE plan to derive revenues from software licenses from developed
products according to an agreed schedule to be determined.

BUTTERFLY PRODUCT CONCEPT

The Butterfly product concept is to provide wide-spread image distribution over
both LAN and WAN combining "Web" technology with compression technology.  More
specifically, the concept is to develop:

 .    A browser based client application that provides sufficient capabilities to
     allow effective review of both diagnostic and referral quality radiology,
     pathology and other types of medical images.  It should also provide
     interactive multimedia capabilities to allow reporting, synchronous
     consultation, and medical record review.

 .    A server that manages the collection, storage and distribution of
     multimedia medical information including images, text, video and audio.
     The server should also provide compression capabilities, configurable
     workflow tools, and DICOM/HL7/http interfaces.

The Butterfly product focuses not only on image distribution but also on
improving workflow within the environment of use. As such, the product
architecture will embrace component technology e.g. COM, and provide "task
centric" operation at both the client and server.

                            CONFIDENTIAL TREATMENT

                                      -25-
<PAGE>

ASSIGNMENT OF RESPONSIBILITIES AND WORK

Broad responsibilities will be assigned as follows:

<TABLE>
<CAPTION>
 ACCESS ACTIVITIES                              AWARE ACTIVITIES
<S>                                             <C>
---------------------------------------------------------------------------------------------------------
Product Definition                                     Assist in Product Definition
---------------------------------------------------------------------------------------------------------

Primary Web Compression Server Application             .  Primary Client Software Development
 Software Development                                  .  Sole Provider/Developer of Compression
                                                             Software Medical Library
                                                       .  Primary Web Interface Level (CGI) Server
                                                             Software Development
                                                       .  Secondary Server Application Software
                                                             Development
---------------------------------------------------------------------------------------------------------
Overall Project Management                             Internal Project Management
---------------------------------------------------------------------------------------------------------
Clinical Site Management
---------------------------------------------------------------------------------------------------------
Regulatory Affairs and Filings
---------------------------------------------------------------------------------------------------------
Good Manufacturing Practices                           Compliance with GMP Software Development
                                                       Requirements
---------------------------------------------------------------------------------------------------------
Medical Direct and OEM Channel Sales & Marketing       Cross-License non-Medical Marketing
---------------------------------------------------------------------------------------------------------
Ongoing Server Application Software Support            Ongoing Client, Server Component, and Compression
                                                       Software Support
---------------------------------------------------------------------------------------------------------
Installation & Customer Support
---------------------------------------------------------------------------------------------------------
Complaint Handling
---------------------------------------------------------------------------------------------------------
License & Revenue Accounting                           Periodic Examination
---------------------------------------------------------------------------------------------------------
</TABLE>

                            CONFIDENTIAL TREATMENT

                                      -26-
<PAGE>

ANTICIPATED TIMETABLES & KEY EVENTS
<TABLE>
<CAPTION>
----------------------------------------------------------------------------------------------------------
TASK                                                              RESPONSIBILITY                 DATE
<S>                                                             <C>                       <C>
----------------------------------------------------------------------------------------------------------
Complete Term Sheet                                             ACCESS, AWARE                    4/18/98
----------------------------------------------------------------------------------------------------------
Complete Contract                                               ACCESS, AWARE                    5/28/97
----------------------------------------------------------------------------------------------------------
Announce to Market                                              ACCESS, AWARE                    TBD
----------------------------------------------------------------------------------------------------------
Complete Regulatory Review                                      ACCESS                           6/21/97
Complete Regulatory 510(k) Filings as Needed                    ACCESS
----------------------------------------------------------------------------------------------------------
Complete Functional Specification                               ACCESS
Review Functional Specification                                 AWARE
Finalize Functional Specification                               ACCESS                           6/30/97
----------------------------------------------------------------------------------------------------------
Complete Product and Software Delivery Plan                     ACCESS                            7/7/97
----------------------------------------------------------------------------------------------------------
Sign up Clinical Beta Partners                                  ACCESS                           6/30/97
----------------------------------------------------------------------------------------------------------
Complete Server Application Design Specification                ACCESS
Complete Server CGI Design Specification                        AWARE
Complete Client Design Specification                            AWARE
Complete Review of Design Specifications                        ACCESS & AWARE
Finalize Design Specification                                   ACCESS                            8/1/97
----------------------------------------------------------------------------------------------------------
Complete Operational Plan including:                            ACCESS                            8/1/97
Strategy and Global market Positioning
  Sales & Marketing
  Packaging & Pricing
  Sales Forecasts
  P & L
----------------------------------------------------------------------------------------------------------
Complete Test Plans                                             ACCESS & AWARE                    8/1/97
----------------------------------------------------------------------------------------------------------
Complete Alpha Development & Testing                            ACCESS & AWARE                  11/15/97
----------------------------------------------------------------------------------------------------------
Start Beta Testing                                              ACCESS                          11/15/97
----------------------------------------------------------------------------------------------------------
Receive FDA 510(k) Market Clearance                             FDA                              12/1/97
----------------------------------------------------------------------------------------------------------
Implement Installation and Support Staff Ramp-up Plan           ACCESS                            1/1/98
----------------------------------------------------------------------------------------------------------
Product Sales and Marketing Launch                              ACCESS                           12/1/97
----------------------------------------------------------------------------------------------------------
Complete First Phase Beta                                       ACCESS                            1/1/97
----------------------------------------------------------------------------------------------------------
Complete GMA Documentation and Notification of Validation &     ACCESS                            1/1/98
 Testing to FDA
----------------------------------------------------------------------------------------------------------
Complete Customer Support Plan                                  ACCESS                            1/1/98
----------------------------------------------------------------------------------------------------------
Begin US Commercialization                                      ACCESS                            1/1/98
----------------------------------------------------------------------------------------------------------
Install West Coast and International End-User Partnership       ACCESS                           1/15/97
 Accounts
----------------------------------------------------------------------------------------------------------
Support and Release Products Accordingly                        ACCESS & AWARE                   On-going
----------------------------------------------------------------------------------------------------------
</TABLE>

                            CONFIDENTIAL TREATMENT

                                      -27-
<PAGE>

                            SCHEDULE 3:  TRADEMARKS

FrameWave is a registered trademark belonging to ACCESS Radiology Corporation.

AccuPress for Radiology is a registered trademark belonging to AWARE, Inc.

                            CONFIDENTIAL TREATMENT

                                      -28-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00002-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00002-of-00352.parquet"}]]